Developer of rare-disease drugs gets $4.6M boost

05/17/2013 | American City Business Journals

A Series A funding round has brought in $4.6 million for Callidus Biopharma, a development-stage biotech firm specializing in rare-disease drugs. The Pennsylvania-based company plans to use the proceeds mainly to speed up preclinical development of its drug candidates for lysosomal storage disorders, including Pompe and Gaucher diseases. Money also will go toward the launch of the firm's proprietary protein-expression technology.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY